How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025 (JSON)

lexblog.com/lib/XZ7RPMJ3view recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025",
    "url": "https://www.oshachronicle.com/2026/11/10/new-congress-same-osha/?utm_source=rss&utm_medium=rss&utm_campaign=new-congress-same-osha",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-XZ7RPMJ3",
        "url": "https://www.lexblog.com/lib/XZ7RPMJ3/"
    },
    "datePublished": "2025-01-14T10:04:55-05:00",
    "dateModified": "2025-01-14T07:11:36-05:00",
    "author": {
        "@type": "Person",
        "name": "Aydin H. Harston, Alex Shaver"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.biosimilarsip.com/?p=5737",
    "sourceStability": "may-move"
}